|1.||Matsubara, Shigeki: 4 articles (06/2011 - 04/2008)|
|2.||Crowther, Caroline A: 3 articles (01/2013 - 01/2010)|
|3.||Matsuda, Yoshio: 3 articles (01/2013 - 01/2002)|
|4.||Suzuki, Mitsuaki: 3 articles (01/2011 - 04/2008)|
|5.||Kuwata, Tomoyuki: 3 articles (01/2011 - 04/2008)|
|6.||Fujimura, Akio: 2 articles (03/2013 - 04/2012)|
|7.||Tsuchiya, Hiroyoshi: 2 articles (03/2013 - 04/2012)|
|8.||Fujiwara, Yoko: 2 articles (03/2013 - 04/2012)|
|9.||Makino, Yasuo: 2 articles (01/2013 - 03/2012)|
|10.||Matsui, Hideo: 2 articles (01/2013 - 03/2012)|
|1.||Premature Obstetric Labor (Premature Labor)
02/01/2006 - "To assess the efficacy of oral ritodrine in the form of sustained-release capsules for maintenance of uterine quiescence after successful treatment of threatened preterm labor. "
09/01/1994 - "Initial parenteral therapy with intramuscular ritodrine hydrochloride is safe and effective and may provide an alternative to intravenous therapy and a means of managing preterm labor during interhospital transport of a patient."
01/01/2014 - "This study aimed to evaluate the effects of β2-adrenergic receptor (ADRB2) gene polymorphisms on ritodrine therapy outcomes in patients with preterm labor. "
03/08/2013 - "Therefore, our study provides a method for sensitive and early detection of hepatic injury, and may thus help preclude serious liver damage due to ritodrine use in preterm labor."
06/01/1991 - "In order to prove the usefulness of the left-lateral position (l-lat.) in preventing the cardiovascular complications associated with ritodrine, twenty-nine patients having preterm labor were employed as the subjects of this study. "
|2.||Birth Weight (Birth Weights)
07/01/1980 - "When compared with controls, there was, among offspring of ritodrine-treated mothers, a significantly reduced incidence of neonatal death and respiratory distress syndrome (P less than .05 in both comparisons) and a significantly higher proportion of infants achieving 36 weeks' gestation (P less than .05) or birth weight greater than 2500 g (P less than .05). "
02/01/2005 - "We abstracted data about delay of gestation, gestational age at delivery, birth weight, severe neonatal respiratory system diseases, perinatal deaths, and administration to contraction-ceased interval, etc. The odds ratio (OR) of 1 day (d) delay in 10 RCTs on ritodrine in preterm labour versus placebo was 2.95 (95%CI 2.15, 4.04), and OR of 2d delay was 1.91 (95%CI 1.49, 2.45), both differences were statistically significant. "
07/30/1992 - "Secondary objectives were the evaluation of the causes of perinatal death, the extent to which delivery was delayed with ritodrine, and the effects on birth weight, maternal morbidity, neonatal morbidity, and infant morbidity at 18 months of postnatal age, corrected for preterm delivery. "
05/01/1986 - "The ritodrine treatment did not have a statistically significant effect on birth weight, gestational age, or the incidence of low birth weight. "
10/15/1980 - "In singleton pregnancies the gestational length and birth weight of the newborn infants were greater in the steroid treatment group (N = 23, 39.1 +/- 0.3 weeks, 3,460 +/- 119 gm) than in the ritodrine group (N = 24, 37.7 +/- 0.4 weeks, 3,106 +/- 118 gm). "
|3.||Newborn Respiratory Distress Syndrome
08/01/1987 - "We speculate that preferential beta-2 adrenergic stimulation of the fetal lung with ritodrine could be helpful in the prevention of neonatal respiratory distress syndrome because of enhanced surfactant availability in airways and improved pulmonary mechanics."
09/01/1990 - "We retrospectively studied 209 patients treated with ritodrine hydrochloride to determine whether change in cervical effacement or dilatation during a period of observation before therapy would result in decreased efficacy of ritodrine, as measured by delivery delays of 48 hours, 1 week, or until greater than or equal to 37 weeks' gestation; neonatal intensive care unit admission; and neonatal respiratory distress syndrome. "
01/01/2015 - "However, maternal side effects such as tachycardia was more frequent (p<0.05) in the ritodrine group. "
03/01/1988 - "Suggested treatment for ritodrine-induced tachycardia in the parturient are presented."
10/01/1979 - "The infusion of ritodrine in doses sufficient to inhibit uterine activity provoked tachycardia, and the cardiac output tended to rise. "
07/15/1978 - "Ritodrine caused significant maternal and fetal tachycardia. "
04/15/1977 - "The most frequent side effects of ritodrine were tachycardia and blood pressure changes which were easily controlled by lowering the infusion rate. "
11/19/1988 - "Reasons for exclusion were: refusal, antepartum haemorrhage, cardiac disease, breech presentation, multiple pregnancy, intrauterine death, and, after May 1986, ritodrine given two hours before delivery, anticoagulant treatment, and any condition needing a particular management of third stage. "
01/01/2005 - "To study the effect of ritodrine tocolysis on the success of external cephalic version (ECV) and to assess the role of ECV in breech presentation at our centre. "
01/01/2005 - "External cephalic version significantly reduced the rate of cesarean section in breech presentation, and ritodrine tocolysis improved the success of ECV and should be offered to both nulliparous and parous women in the case of term breech presentation."
|2.||Magnesium Sulfate (Sulfate, Magnesium)
|7.||Adrenergic beta-Agonists (beta-Adrenergic Agonists)
|9.||Ethanol (Ethyl Alcohol)
|3.||Fetal Version (External Cephalic Version)
|4.||Cesarean Section (Caesarean Section)
|5.||Neonatal Intensive Care